The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by BLACK, D. W.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by BLACK, D. W.
Related Collections
* Somatoform Disorders
* Antidepressants
Am J Psychiatry 159:1436-1437, August 2002
© 2002 American Psychiatric Association


Letter to the Editor

Paroxetine for Multiple Chemical Sensitivity Syndrome

DONALD W. BLACK, M.D.
Iowa City, Iowa

To the Editor: Multiple chemical sensitivity syndrome is thought by some to be caused by extreme sensitivity to chemical "incitants" in concentrations that are ordinarily well tolerated (1). These patients typically report multiple somatic complaints and develop behavioral changes congruent with their beliefs about symptom causation. We report on a woman who was successfully treated for this condition with paroxetine.

Ms. A was a 44-year-old woman who had developed a fear of strong chemical odors 2 years earlier after exposure to natural gas at work over a 2-week period. She reported episodic lightheadedness, a tingling of her lips, and an unsteady gait. She was moved to another part of the work site, and her symptoms disappeared. Several weeks later, after returning to her usual workstation, she developed diffuse muscle weakness, headache, nausea, and cloudy vision. An emergency medical team arranged for her to be flown to a tertiary care medical center 80 miles away. Results of a medical evaluation were unremarkable, and she was discharged the next day.

Over the ensuing months, Ms. A developed "reactions" when exposed to strong odors, which led her to alter her behavior. She stopped working and avoided attending church and shopping. She was diagnosed with multiple chemical sensitivity syndrome and subsequently obtained workers’ compensation.

Ms. A was referred to the psychiatry department for evaluation. She had mild depression that did not fulfill criteria for major depressive disorder. She expressed a fear of chemical odors and described "reactions" that were identical to panic attacks. She was diagnosed with panic disorder with agoraphobia and was treated with paroxetine, 20 mg/day; her dose was gradually increased to 40 mg/day. Trazodone, 100 mg at bedtime, was prescribed.

Within 3 months, Ms. A was no longer depressed, and her "reactions" to chemical odors had stopped. She was able to shop unaccompanied and attend church. By her 5-month follow-up, Ms. A had returned to work and remained free of the "reactions." She has now been followed for nearly 4 years while receiving maintenance treatment with paroxetine, 40 mg/day, and trazodone, 100 mg at bedtime; she continues to be symptom free. She still believes that chemical odors induced her multiple chemical sensitivity syndrome.

The treatment of patients diagnosed with multiple chemical sensitivity syndrome has been troublesome and has generally been the province of nontraditional medical practitioners. This case joins two others (2, 3) in showing that some patients diagnosed with multiple chemical sensitivity syndrome have an underlying psychiatric disorder that, when identified, responds to medication therapy.

References

  1. Black DW, Doebbeling BN, Voelker MD, Clarke WR, Woolson RF, Barrett DH, Schwartz DA: Multiple chemical sensitivity syndrome: symptom prevalence and risk factors in a military population. Arch Intern Med 2000; 160:1169-1176[Abstract/Free Full Text]
  2. Stenn P, Binkley K: Successful outcome in a patient with chemical sensitivity: treatment with psychological desensitization and selective serotonin reuptake inhibitor. Psychosomatics 1998; 39:547-550[Free Full Text]
  3. Andine P, Rönnback L, Järvholm B: Successful use of a selective serotonin reuptake inhibitor in a patient with multiple chemical sensitivities. Acta Psychiatr Scand 1997; 96:82-83[Medline]




This Article
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by BLACK, D. W.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by BLACK, D. W.
Related Collections
* Somatoform Disorders
* Antidepressants


Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org